Welcome to our dedicated page for Renovorx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on Renovorx stock.
RenovoRx, Inc. reports news on targeted oncology drug delivery, the commercialization of RenovoCath®, and clinical development of its TAMP™ therapy platform. The company is a life-sciences issuer developing localized cancer therapies and commercializing RenovoCath, a patented FDA-cleared drug-delivery device used for temporary vessel occlusion and chemotherapeutic drug infusion.
Recurring updates cover RenovoCath adoption at U.S. cancer centers, intellectual-property protection for the device, financing activity, financial results, and presentations of clinical or pharmacologic data. News also tracks IAG, the investigational intra-arterial gemcitabine product candidate delivered via RenovoCath, including disclosures tied to the TIGeR-PaC trial in locally advanced pancreatic cancer and orphan drug designations for pancreatic and bile duct cancer.
RenovoRx, a biopharmaceutical company, announced FDA 510(k) clearance for its RenovoCath Delivery System, integral to its RenovoGem product. This dual-balloon catheter enhances targeted chemotherapy delivery to tumors, potentially improving treatment efficacy with reduced side effects. The RenovoTAMP platform, currently in the Phase 3 TIGeR-PaC clinical trial for pancreatic cancer, has seen 44% patient enrollment. In previous studies, over half of treated patients survived beyond two years, significantly better than the typical 12-15 months for standard care.